The FDA has approved a trial investigating the use of bone marrow derived cells in Autism spectrum disorders (ASD). While anecdotal findings might support this approach, there is mixed feeling on the scientific rationale for this trial. The most likely premiss seems – ASDs are associated with severe immune alterations and pro-inflammatory cytokines overproduction and bone marrow cells could address this through an immuno-modulatory action. http://www.scitechnol.com/JRGM/JRGM-1-e103.pdf
Stem cell small caps – high risk / high reward stock?
In this innovative medicinal technique Professor John S. Yu genetically modified stem cells to produce Vascular endothelial growth factor (VEGF) – a protein that stimulates neo-vascularization. The cells were then used to treat diabetes in mice:http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0042177
The study found “Human BMSCs expressing VEGF and PDX1 reversed hyperglycemia in more than half of the diabetic mice and induced overall improved survival and weight maintenance in all mice”
Most interestingly the study found that endogenous β-cell regeneration seemed to drive the benefits.